Potential for More Rational Use of Antibiotics in Hospitalized Children in a Country with Low Resistance - Data From Eight Point Prevalence Surveys

The Pediatric Infectious Disease Journal
Christian Magnus ThaulowHege Salvesen Blix

Abstract

Antimicrobial resistance (AMR) is low in Norway, but to prevent an increase the Norwegian Government has launched a National Strategy including a 30% reduction of broad-spectrum antibiotics (BSA) in hospitals within 2020. BSA are defined as second- and third-generation cephalosporins, carbapenems, piperacillin/tazobactam and quinolones. There are no recent studies of antibiotic use in Norwegian hospitalized children. To describe the use of antibiotics with emphasis on BSA in Norwegian hospitalized children and neonates in order to detect possibilities for optimization. Data were extracted from eight national point prevalence surveys of systemic antibiotic prescriptions in Norwegian hospitals between 2015 and 2017. The choices of antibiotics were compared with the empirical recommendations given in available Norwegian guidelines. In total, 1323 prescriptions were issued for 937 patients. Twenty-four percent of pediatric inpatients were given antibiotics. Adherence to guidelines was 48%, and 30% (95% CI 27%-33%) of all patients on antibiotics received BSA. We identified only small variations in use of BSA between hospitals. One third of the patients on antibiotic therapy received prophylaxis whereof 13% where given BSA. In 30% of...Continue Reading

References

Aug 1, 1997·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·E EsbjörnerS Hansson
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F BaqueroJ Blázquez
Aug 16, 2003·The Journal of Hospital Infection·S HarbarthP Gastmeier
Mar 11, 2005·Mayo Clinic Proceedings·Miguel A Park, James T C Li
Oct 6, 2007·Scandinavian Journal of Infectious Diseases·Niklas StabellClaus Klingenberg
Apr 25, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H Goossens
Mar 2, 2012·The Journal of Antimicrobial Chemotherapy·Alessandro PortaMike Sharland
Apr 23, 2013·The Journal of Antimicrobial Chemotherapy·Heather J AdamUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA)
Sep 30, 2014·JAMA Pediatrics·L Charles BaileyPatricia A DeRusso
Nov 26, 2015·The Pediatric Infectious Disease Journal·Are Stuwitz BergBritt Nakstad
Jan 27, 2016·Nature Communications·Katri KorpelaWillem M de Vos
Apr 14, 2016·The Pediatric Infectious Disease Journal·Patricia L Hibberd, Shamim A Qazi
Oct 30, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D TorfossS Kvaløy
Dec 10, 2016·Acta Paediatrica·Martin DragesetClaus Klingenberg
Mar 9, 2017·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Øyunn HolenHanne Merete Eriksen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.